- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03864536
A Multidomain Approach to Preventing Dementia in African Americans: Cognitive Prescriptions
November 30, 2022 updated by: Pariya L. Fazeli, PhD, University of Alabama at Birmingham
The goal of this R21 study is to explore the feasibility and preliminary efficacy of individualized cognitive prescriptions (CogRxs) in improving engagement in healthy behaviors and other outcomes in middle-aged AAs and to gain feedback on future implementation of the program.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A pre-post experimental design will be used, in which 150 AA participants aged 50-65 will complete a baseline assessment of cognitive testing and data-driven assessment of deficiencies across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity).
Participants will be randomized to either: psychoeducation + CogRx, psychoeducation only, or no contact control.
The psychoeducation and CogRx groups will receive general psychoeducation on dementia prevalence, prognosis, and risk factors, while the CogRx group will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
Motivational reminders as well as adherence and self-efficacy questions will be administered via text-messaging over the 3-months.
Participants will return for 3-month and 6-month follow-ups.
Specific Aim 1 (proximal outcomes) is to determine whether the CogRx condition is superior to psychoeducation alone in improving engagement in healthy lifestyle behaviors.
Specific Aim 2 (distal outcomes) is to compare the three conditions on a brief battery of cognitive and psychological measures.
The Exploratory Aim is to gather feedback for future implementation of this program, including cultural considerations, barriers and facilitators to engagement, and likelihood of continuing the program.
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- the Holly Mears Building/Center for Research on Applied Gerontology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusions:
- Must be African American
- Must be age 50 to 65
- Must have a working cell phone with unlimited texting
- Must be ambulatory
Exclusions:
- No neurological (including dementia diagnosis) or severe psychiatric (e.g., schizophrenia or bipolar disorder) disorders
- No insomnia
- Telephone Interview for Cognitive Status (TICS) score ≤20
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No-contact control
|
|
Active Comparator: Psychoeducation control
Receives general psychoeducation on dementia prevalence, prognosis, and risk factors,
|
Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
Other Names:
|
Experimental: Psychoeducation + CogRx
Receives same general psychoeducation on dementia and will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
|
Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Behavior Composite Score
Time Frame: change from baseline to 3 months
|
Physical activity, cognitive activity, diet, sleep, and social activity are the primary outcome, as the goal of the intervention is to improve behaviors the participant is determined to have deficiencies in at baseline.
Since the intervention is tailored, outcomes are unique (e.g., one persons intervention might consist of improving physical activity and diet, whereas another might focus on cognitive activity and sleep).
The following self-reported questionnaires will be used: Physical activity (the International Physical Activity Questionnaire), Diet (the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) questionnaire), Social Activity (the Duke Social Support Inventory), Sleep (the Pittsburg Sleep Quality Index (PSQI)), Cognitive Activity (a modified Florida Cognitive Activities Scale).
Cutoffs will be used to create dichotomies for each domain such that 1=optimal and 0=suboptimal, which will be summed to create a Health Behavior composite (scores ranging from 0-5).
|
change from baseline to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dementia Knowledge
Time Frame: change from baseline to 3 months
|
Scores on the Dementia Knowledge Assessment Scale (DKAS-27) which assesses knowledge about risk factors and prognosis of dementia.
Scores include percentage correct for the 27 items, with scores ranging from 0-100%.
|
change from baseline to 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Pariya Wheeler, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2020
Primary Completion (Actual)
January 30, 2022
Study Completion (Actual)
January 30, 2022
Study Registration Dates
First Submitted
February 28, 2019
First Submitted That Met QC Criteria
March 5, 2019
First Posted (Actual)
March 6, 2019
Study Record Updates
Last Update Posted (Actual)
December 1, 2022
Last Update Submitted That Met QC Criteria
November 30, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Cognitive Prescriptions
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Change
-
University Ramon LlullAinhoa Nieto Guisado; Mònica Solana-TramuntUnknownCognitive Change | Proprioception Change | Balance ChangeSpain
-
Applied Science & Performance InstituteRecruitingCognitive Change | Mood Change | Mental ProcessesUnited States
-
National Council of Scientific and Technical Research...CompletedSleep | Cognitive Change | Mood Change | CreativityArgentina
-
Wake Forest UniversityNot yet recruiting
-
Biruni UniversityCompletedCognitive ChangeTurkey
-
University of MemphisCalerie LLCCompletedCognitive ChangeUnited States
-
Oregon Health and Science UniversityCompleted
-
University of MiamiUnited States Department of DefenseCompleted
-
Northumbria UniversityPerfetti van Melle SPACompletedCognitive ChangeUnited Kingdom
-
Universidad de GranadaCompleted
Clinical Trials on Cognitive Prescriptions
-
Johns Hopkins UniversityNational Library of Medicine (NLM)CompletedMedication Adherence | Patient Compliance | Medication Non-AdherenceUnited States
-
Gaziler Physical Medicine and Rehabilitation Education...Completed
-
Johns Hopkins UniversityNational Institutes of Health (NIH); National Library of Medicine (NLM)Completed
-
xulingCompletedNon-small Cell Lung CancerChina
-
University Hospital, BordeauxUniversity of BordeauxRecruitingSurgery | AntibioticFrance
-
Shanghai University of Traditional Chinese MedicineShanghai Chest Hospital; Shanghai Cancer Hospital, China; Shanghai Pulmonary... and other collaboratorsUnknownNon-small Cell Lung CancerChina
-
Shanghai University of Traditional Chinese MedicineShanghai Chest Hospital; Shanghai Cancer Hospital, China; Shanghai Pulmonary... and other collaboratorsUnknownNon-small Cell Lung CancerChina
-
Jiangsu Famous Medical Technology Co., Ltd.Completed
-
VA Pharmacy Benefits Management Strategic Healthcare...CompletedHypertensionUnited States
-
Uppsala UniversityLund UniversityCompleted